HomeInsightsStock Comparison

Marksans Pharma Ltd vs Piramal Pharma Ltd Stock Comparison

Marksans Pharma Ltd vs Piramal Pharma Ltd Stock Comparison

Last Updated on: Aug 02, 2025

Key Highlights

  • The Latest Trading Price of Marksans Pharma Ltd is ₹ 224.6 as of 01 Aug 15:30.
  • The P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 26.5 on March 2025 . This represents a CAGR of 33.41% over 6 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 years.
  • The Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 10076 crore on March 2025 . This represents a CAGR of 61.45% over 6 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 29763 crore on March 2025 . This represents a CAGR of 53.90% over 3 years.
  • The revenue of Marksans Pharma Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 724.98 crore. This represent the decline of -100% The revenue of Piramal Pharma Ltd for the Jun '25 is ₹ 2031 crore as compare to the Mar '25 revenue of ₹ 2812 crore. This represent the decline of -27.77%.
  • The ebitda of Marksans Pharma Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 142.27 crore. This represent the decline of -100% The ebitda of Piramal Pharma Ltd for the Jun '25 is ₹ 204.41 crore as compare to the Mar '25 ebitda of ₹ 619.24 crore. This represent the decline of -66.99%.
  • The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Piramal Pharma Ltd changed from ₹ -98.58 crore to ₹ -81.7 crore over 9 quarters. This represents a CAGR of -8.01% .
  • The Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 19.26 % on March 2025 . This represents a CAGR of 10.12% over 6 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

About Piramal Pharma Ltd

  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
  • It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
  • It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Marksans Pharma Ltd News Hub

News

Marksans Pharma schedules board meeting

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 12 August ...

Read more

25 Jul 2025 10:49

News

Marksans Pharma AGM scheduled

Marksans Pharma announced that the 33th Annual General Meeting(AGM) of the company will be...

Read more

11 Jul 2025 17:41

News

Time-Cap Laboratories successfully concludes USFDA inspection

Marksans Pharma announced that its subsidiary, Time-Cap Laboratories Inc. has received the...

Read more

30 Jun 2025 12:56

News

Marksans Pharma rises after subsidiary gets EIR for New York-based facility from US FDA

In April this year, the United States Food and Drug Administration (US FDA) had conducted ...

Read more

30 Jun 2025 12:58

News

Marksans Pharma's UK arm gets marketing nod for Oxybutynin Oral solution from UKMHRA

Oxybutynin is used in the treatment of overactive bladder (OAB) symptoms. OAB is a collect...

Read more

19 Jun 2025 10:04

News

Relonchem receives marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution in UK

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

30 May 2025 09:13

Piramal Pharma Ltd News Hub

News

Piramal Pharma grants 20,20,507 stock options

The Board of Piramal Pharma at its meeting held on 28 July 2025 has approved the grant of ...

Read more

29 Jul 2025 09:47

News

Piramal Pharma posts loss of Rs 82 crore in Q1; EBITDA margin declines to 9%

Revenue from operations for the period under review declined by 1% year-over-year (YoY) to...

Read more

29 Jul 2025 09:30

News

Piramal Pharma to sell its decommissioned unit in MIDC, Thane for Rs 8.50 cr

Piramal Pharma announced that the Administrative Committee of the Board, at its meeting he...

Read more

22 Jul 2025 16:23

News

Piramal Pharma receives upgrade in LT credit ratings

Piramal Pharma announced that CARE has revised the credit ratings assigned to the company ...

Read more

21 Jul 2025 13:15

News

Piramal Pharma to announce Quarterly Result

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 28 July 202...

Read more

19 Jul 2025 09:22

News

Piramal Pharma to conduct AGM

Piramal Pharma announced that the 5th Annual General Meeting(AGM) of the company will be h...

Read more

14 Jun 2025 14:54

SWOT Analysis Of Piramal Pharma Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Piramal Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Marksans Pharma Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Marksans Pharma Ltd or Piramal Pharma Ltd?

Market cap of Marksans Pharma Ltd is 10,178 Cr while Market cap of Piramal Pharma Ltd is 25,335 Cr

What are the key factors driving the stock performance of Marksans Pharma Ltd and Piramal Pharma Ltd?

The stock performance of Marksans Pharma Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Marksans Pharma Ltd and Piramal Pharma Ltd?

As of August 2, 2025, the Marksans Pharma Ltd stock price is INR ₹224.6. On the other hand, Piramal Pharma Ltd stock price is INR ₹190.6.

How do dividend payouts of Marksans Pharma Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Marksans Pharma Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions